CEPHEID (CPHD)

Cepheid, Inc. operates as a molecular diagnostics company that develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection. The company offers emergency use authorization, the GeneXpert system for testing in the areas of healthcare-associated infections, critical infectious diseases, sexual health, virology, oncology, and genetics. It also provides the SmartCycler system, which integrates DNA amplification and detection to allow the analysis of a sample and Xpert tests for use on the GeneXpert system. The company sells its products through its direct sales force and distributors worldwide. It has collaboration arrangements with Life Technologies Corporation to develop reagents for use in the USPS BDS program; the Foundation for Innovative New Diagnostics to develop tests that can detect Mycobacterium tuberculosis and associated rifampin resistance from human sputum samples; the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert Ebola, an Ebola test to be run on its GeneXpert Systems; and Sherlock Biosciences to explore the development of new molecular diagnostic tests. The company was incorporated in 1996 and is based in Sunnyvale, California. Cepheid, Inc. operates as a subsidiary of Danaher Corporation.